Patents/Assignees

Allogene Therapeutics, Inc.

15 patents in portfolio

US12577283utility2026
Knockdown or Knockout of One or More of TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK to Mitigate T Cell Recognition of Allogeneic Cell Products
0 cites
US12577290utility2026
Fasl Expression and Fasr Gene Knockout to Protect Therapeutic Cells from Allogeneic Rejection and Activation-induced Cell Death
0 cites
US12528856utility2026
Chimeric Cytokine Receptors Comprising TGF Β Binding Domains
0 cites
US12447178utility2025
Method of Treatment Using Anti-cd19 Rituximab-resistant Chimeric Antigen Receptors
0 cites
US12365873utility2025
Methods for Transducing Immune Cells
0 cites
US12295362utility2025
Formulations and Processes for CAR T Cell Drug Products
0 cites
US12215347utility2025
Chimeric Antigen Receptors with Enhanced Signaling and Activities and Uses Thereof
0 cites
US12163153utility2024
Methods of Manufacturing Allogeneic CAR T Cells
0 cites
US12163169utility2024
Inducible Chimeric Cytokine Receptors
0 cites
US12104188utility2024
Modified Caspase-9 Polypeptides and Methods of Use Thereof
0 cites
US12043655utility2024
Constitutively Active Chimeric Cytokine Receptors
0 cites
US12036243utility2024
BCMA CAR-T Cells with Enhanced Activities
0 cites
US11896617utility2024
Polynucleotides Encoding Rituximab-resistant Chimeric Antigen Receptors
0 cites
US11781248utility2023
Anti-talen Antibodies and Uses Thereof
0 cites
US11732041utility2023
Antibodies Against 4g7-derived Chimeric Antigen Receptors
0 cites